Research programme: SMARCA2 protein degraders - Prelude Therapeutics

Alternative Names: SMARCA2 degraders - Prelude Therapeutics; SMARCA2 selective degraders - Prelude Therapeutics

Latest Information Update: 14 Dec 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

11 Dec 2023 Prelude Therapeutics plans a phase I trial for Cancer in second half of 2024
03 Aug 2023 Prelude Therapeutics plans to file an IND application in early 2024.
14 Apr 2023 Preclinical trials in Cancer in USA (PO) prior to April 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com